Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study

被引:180
作者
Gur, C
Diav-Citrin, O
Shechtman, S
Arnon, J
Ornoy, A
机构
[1] Israeli Minist Hlth, Israeli Teratogen Informat Serv, Hadassah Med Sch, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Israeli Minist Hlth, IL-91120 Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Anat & Cell Biol, Lab Teratol, IL-91120 Jerusalem, Israel
关键词
glucocorticosteroids; prednisone; pregnancy; congenital anomalies;
D O I
10.1016/j.reprotox.2003.10.007
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: To evaluate the safety of glucocorticosteroids (GCS) in pregnancy. Study design: The Israeli Teratogen Information Service (TIS) prospectively collected and followed 311 pregnancies counseled regarding systemic use of different GCS in the first trimester. The rate of major congenital anomalies was compared to that of 790 controls who were counseled for non-teratogenic exposure. Results: The rate of major anomalies did not significantly differ between the groups [12/262 = 4.6% (GCS), 19/728 = 2.6% (control), P = 0.116]. There was no case of oral cleft and no pattern of anomalies among the GCS exposed group. Higher rates of miscarriages (11.5% versus 7.0%, P = 0.013) and preterm births (22.7% versus 10.8%, P < 0.001) were observed among the GCS exposed group compared to the controls. GCS exposed infants had a lower median birth weight [3080g versus 3290g, P < 0.001] and were born at an earlier median gestational age [39 weeks versus 40, P < 0.001] compared to the control. Conclusions: The present study supports that GCS do not represent a major teratogenic risk in humans. The study was powered to find a 2.5-fold increase in the overall rate of major anomalies. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:93 / 101
页数:9
相关论文
共 36 条
[1]  
BEHRMAN RE, 1987, NELSON TXB PEDIAT, P268
[2]  
BRIGGS GG, 2002, DRUGS PREGNANCY LACT, P326
[3]  
Carmichael SL, 1999, AM J MED GENET, V86, P242, DOI 10.1002/(SICI)1096-8628(19990917)86:3<242::AID-AJMG9>3.0.CO
[4]  
2-U
[5]  
CUNNINGHAM FG, 1997, WILLIAMS OBSTETRICS, P2579
[6]  
Czeizel AE, 1997, TERATOLOGY, V56, P335, DOI 10.1002/(SICI)1096-9926(199711)56:5<335::AID-TERA7>3.0.CO
[7]  
2-W
[8]   Pregnancy outcome after gestational exposure to metronidazole: A prospective controlled cohort study [J].
Diav-Citrin, O ;
Shechtman, S ;
Gotteiner, T ;
Arnon, J ;
Ornoy, A .
TERATOLOGY, 2001, 63 (05) :186-192
[9]  
DOIG RK, 1956, LANCET, V2, P730
[10]   SYSTEMIC LUPUS-ERYTHEMATOSUS IN PREGNANCY [J].
FINE, LG ;
BARNETT, EV ;
DANOVITCH, GM ;
NISSENSON, AR ;
CONOLLY, ME ;
LIEB, SM ;
BARRETT, CT .
ANNALS OF INTERNAL MEDICINE, 1981, 94 (05) :667-677